Dateline — San Diego, California, November 7, 2025:
Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported Q3 2025 financial results and a comprehensive business update, showcasing both strong commercial performance and advancing clinical development across its fibrosis-focused pipeline. The company achieved net income of $5.9 million, up 100% year-over-year, and quarterly revenue of $30.6 million, reflecting 20% growth driven by robust sales of ETUARY®, Etorel®, and Contiva®. Alongside commercial success, Gyre is progressing its Hydronidone New Drug Application (NDA) in China and preparing for a U.S. Investigational New Drug (IND) submission for MASH-associated liver fibrosis in 2026.
Science Significance
Gyre Therapeutics continues to establish itself as a biopharmaceutical leader in organ fibrosis research. Its Hydronidone, a next-generation analogue of pirfenidone, demonstrated statistically significant fibrosis regression in chronic hepatitis B (CHB)-associated liver fibrosis during a pivotal Phase 3 trial in China. The compound is designed to modulate multiple pro-fibrotic pathways, offering a differentiated mechanism of action across liver and pulmonary fibrotic diseases. Meanwhile, the company’s pirfenidone program completed Phase 3 enrollment in pneumoconiosis (a chronic occupational lung fibrosis) and plans to initiate an adaptive Phase 2/3 trial for oncology-related pulmonary complications, including radiation-induced lung injury (RILI) and immune-related pneumonitis. These scientific efforts reflect Gyre’s multi-organ fibrosis-first strategy aimed at addressing major chronic diseases through precision therapeutic innovation.
Regulatory Significance
Gyre’s regulatory trajectory underscores a balanced global development plan. The Hydronidone NDA is advancing under Priority Review discussions with China’s National Medical Products Administration (NMPA) following the compound’s Breakthrough Therapy designation. In parallel, the U.S. IND filing for MASH-associated liver fibrosis is scheduled for 2026, pending completion of data translation and hepatic impairment studies to meet FDA standards. The company’s meticulous coordination between Chinese and U.S. regulators illustrates a cross-border regulatory strategy aimed at accelerating patient access and aligning with international compliance expectations. Additionally, Gyre’s ongoing Phase 3 pneumoconiosis trial and upcoming oncology fibrosis studies are being conducted under stringent Good Clinical Practice (GCP) frameworks, strengthening the company’s regulatory credibility across multiple jurisdictions.
Business Significance
Advertisement
Financially, Gyre Therapeutics delivered record quarterly revenue of $30.6 million, reflecting sustained demand for ETUARY® (pirfenidone), alongside successful commercial launches of Etorel® (nintedanib) and Contiva® (avatrombopag). Operating income increased 64% to $6.9 million, and adjusted net income reached $8.8 million, signaling strong operational discipline and efficient cost control. Despite revising full-year revenue guidance slightly to $115–118 million due to procurement policy uncertainty in China, the company maintains $80.3 million in cash and deposits, a 57% increase year-to-date. Gyre’s business model integrates commercial profitability with pipeline investment, leveraging its 69.7% controlling interest in Gyre Pharmaceuticals to expand both R&D and market penetration across Asia and the U.S.
Patients’ Significance
For patients suffering from fibrosis-related diseases, Gyre’s progress represents tangible hope. Hydronidone’s clinical success in CHB-related liver fibrosis could deliver the first disease-modifying treatment for this widespread condition in China, offering improved liver function and reduced fibrosis progression. Similarly, pirfenidone’s development in pneumoconiosis and RILI aims to provide new therapeutic options for chronic and occupational lung diseases, where treatment options remain limited. By focusing on safety, long-term efficacy, and accessibility, Gyre is addressing critical unmet needs for patients with multi-organ fibrotic conditions, potentially improving both survival and quality of life.
Policy Significance
Gyre’s cross-border R&D strategy aligns with global health policy trends favoring accelerated access to first-in-class and orphan treatments. The Breakthrough Therapy designation and Priority Review process for Hydronidone in China exemplify regulatory systems that promote innovation for high-burden chronic diseases. Furthermore, Gyre’s adaptation to China’s centralized procurement framework demonstrates the company’s strategic compliance with government-driven healthcare reforms. As fibrosis-related conditions rise globally, Gyre’s data-driven approach supports international policy objectives around biopharma innovation, localization, and patient access to advanced therapeutics.
With a strong balance sheet, expanding global pipeline, and advancing regulatory milestones, Gyre Therapeutics continues to solidify its position as a commercial-stage biopharma innovator in fibrosis treatment. The company’s integrated model—linking R&D excellence, manufacturing quality, and regulatory alignment—positions it for sustainable growth across the U.S. and Asia. As Hydronidone approaches NDA submission and the company advances toward its U.S. MASH program, Gyre Therapeutics stands on the cusp of transforming fibrosis management through a science-driven, patient-centered approach that defines the future of biopharmaceutical innovation.
Source: Gyre Therapeutics press release
